Ad5/F35-Luciferase Chimeric Adenovirus

The Ad5/F35-luciferase chimeric adenovirus is an advanced gene delivery platform that combines the broad tropism of fibrinolytic adenoviruses with the high-sensitivity detection capabilities of luciferase reporter genes. By integrating the fibrin globules and fibrin axes of adenovirus type 35 into the Ad5 backbone, this chimeric vector can transfer genes into cells expressing CD46 but lacking standard CAR receptors, such as hematopoietic stem cells, B cells, and various malignant cell types. The vector exhibits replication defects (dE1/E3), ensuring high safety for laboratory applications. The firefly luciferase gene, driven by a constitutive promoter, generates a highly quantitative and dynamically broad bioluminescent signal upon the addition of luciferin. This system is optimized for high-titer and efficient transduction in previously “refractory” cell types, providing a standardized platform for monitoring gene expression intensity and duration.

The application of the Ad5/F35-luciferase chimeric adenovirus is crucial for researchers focusing on hematopoietic and immunogenetic therapies. It can precisely quantify transduction efficiency in primary human blood cells, providing sensitive detection indicators for optimizing CAR-T or other cell therapy delivery protocols. In oncology research, it is used to monitor gene expression in CAR-negative tumor models, where bioluminescence imaging (BLI) helps track viral distribution and transgene persistence in vivo in real time. Furthermore, the Ad5/F35-luciferase system serves as a powerful tool for high-throughput screening of small molecules that enhance viral entry into specific cell lineages or gene expression. By providing reliable and easily quantifiable markers, this chimeric vector facilitates the transition from basic molecular biology to preclinical trials in complex biological systems, ensuring targeted and measurable gene delivery.